Founders

Andrew Allen, M.D., Ph.D.

Tim Chan, M.D., Ph.D.

Timothy A. Chan is a cancer geneticist and physician scientist with an interest in immunogenomics and immunotherapy.  He is currently Vice Chair of the Department of Radiation Oncology and the Frederick Adler Chair at the Memorial Sloan Kettering Cancer Center (MSKCC). He is a member of the Human Oncology and Pathogenesis Program at MSKCC and director of the Division of Translational Oncology of the Department of Radiation Oncology. Dr. Chan obtained an M.D. and Ph.D. in genetics from the Johns Hopkins School of Medicine.  He went on to complete a residency in radiation oncology and a post-doctoral fellowship in epigenetics.  His main interests are utilizing cancer genomics, functional genomics, and statistical genetics to dissect the molecular determinants of tumor aggressiveness and response to cancer therapies.  He led the team that first described mutational burden as a determinant of clinical benefit to immunotherapy and showed that mutational landscapes in lung cancer help determine response to immune checkpoint blockade. His lab is developing pioneering approaches to examine neo-antigen landscapes and the genomic foundations of response to cancer immunotherapy.  He has contributed publications as first or senior author in journals such as Nature, Science, Cell, Nature Genetics, New England Journal of Medicine, and Science Translational Medicine.

Mark Cobbold, M.D., Ph.D.

Mark Cobbold is an Associate Professor of Medicine at the Massachusetts General Hospital (MGH) Cancer Center. He is a member of the MGH Center for Cancer Immunology and his research focuses on understanding how the healthy human-immune response is able to recognize and target cancerous cells and, when it fails, how it could be strengthened to recognize this threat.  Dr. Cobbold undertook his early clinical training at the University of Edinburgh and followed an academic clinical training path at the University of Birmingham in clinical immunology.  He was awarded a Ph.D. in 2005 for work in antigen-specific cellular immunotherapy for patients who had received a stem-cell transplant.  During this period he developed new methods for manipulating and selecting antigen-specific cells for therapeutic use leveraging MHC class-I tetramers. Cobbold undertook his post-doctoral training at the University of Virginia, identifying modified MHC class-I bound tumor antigens and later exploring immunity against these antigens in both healthy individuals and patients with cancer.  His more recent work has focused on developing new strategies to modify MHC class-I antigen-display to redirect existing immunity against cancer. Cobbold is passionate about translational medicine and is scientific co-founder of several companies including SeraScience Ltd., PhosImmune, Inc., and Revitope Ltd.

Graham Lord, M.D., Ph.D.

Graham Lord is Professor of Medicine at King’s College London, Head of the Department of Experimental Immunobiology, and Director of the NIHR Biomedical Research Center, Guy’s and St. Thomas’ Hospital and King’s College London. Since his appointment in 2006, Dr. Lord has built up a research group at King’s College investigating fundamental immune-cell biology, and the translation of this knowledge to the diagnosis and treatment of patients with organ-transplant rejection and autoimmune diseases. He led the successful application for the NIHR Biomedical Research Centre at Guy's and St Thomas' and was appointed as Director of the Center in 2012. In this role, he is responsible for the delivery of programs of Translational Research and Experimental Medicine with a significant part of the Centers' portfolio focused on Regenerative and Personalized Medicine, Advanced Therapeutics and Informatics. He was elected as an NIHR Senior Investigator in 2013. As an NHS consultant, he practices clinical nephrology with a particular interest in renal and pancreatic transplantation. He originally trained in medicine at Cambridge University and undertook a period of research in Molecular Immunology at Imperial College London that led to a Ph.D. He conducted post-doctoral studies at Harvard University. 

Naiyer Rizvi, M.D.

Naiyer A. Rizvi is a medical oncologist with specific expertise in thoracic oncology and immunotherapy drug development. Dr. Rizvi is the Price Chair of Clinical Translational Medicine at Columbia University Medical Center (CUMC). He is also the Director of Thoracic Oncology and Immunotherapeutics at CUMC. He obtained his M.D. at University of Manitoba in Winnipeg, Canada and went on to complete a fellowship in medical oncology at Beth Israel Hospital/Harvard Medical School. He was an attending physician in thoracic oncology and early drug development from 2002-2014 at Memorial Sloan Kettering Cancer Center (MSKCC). During his last six years at MSKCC, Rizvi’s translational research was focused on immune-checkpoint blockade drug development. His research studies were integral to the approval of immune-checkpoint blockade in lung cancer including approval of nivolumab in squamous lung cancer (Lancet Oncology 2015) and pembrolizumab in non-small cell lung cancer (NEJM, 2015). His first-author publication in Science (2015) presented data from a landmark trial - the first study to demonstrate a statistically significant correlation between mutations and neo-antigens with durable benefit to immune-checkpoint blockade. His ongoing work is to understand mechanisms of sensitivity and resistance to immunotherapy.

Jean-Charles Soria, M.D., Ph.D.

Jean-Charles Soria is a Professor of Medicine and Medical Oncology at South-Paris University and a cancer specialist at Institut Gustave Roussy (IGR) in Paris. Professor Soria is currently Chair of the Drug Development Department at IGR and is a member of the lung cancer unit with a focus on targeted therapies. His main research interests are early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer, and personalized medicine. Soria was a member of the ESMO Executive Committee from 2008 to 2009, and served as an ASCO committee member from 2006 to 2012. He was the scientific chairman of the ECCO-ESMO 2011 meeting held in Stockholm, and chair of the EORTC-NCI-AACR 2014 meeting in Barcelona. He was the President of the TAT meeting in 2013 and 2015 in Paris. Soria has contributed to more than 420 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology. He has been appointed Editor in Chief of Annals of Oncology for 2014-2018. Originally he trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997, then obtained a Ph.D., and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, where he has held an Adjunct Professorship since 2012.